Skip to main content
. 2011 Apr 5;19(8):1511–1520. doi: 10.1038/mt.2011.61

Figure 2.

Figure 2

Effect of interleukin-2 (IL-2) complexes treatment on CD4+ T cells and CD4+CD25+Foxp3+ regulatory T (Treg) cells in periphery blood using schedule 1 treatment. Blood cells were isolated from untreated mice and mice treated with IL-2 complexes only, factor VIII (FVIII) plasmid only and FVIII plasmid + IL-2 complexes (n = 4/group, schedule 1) at serial time points. Cells were stained and analyzed for CD4+ and CD4+CD25+Foxp3+ T cells by flow cytometry. For CD4+ T cells, (a) left panel, representative dot plot from naive and mice treated with FVIII plasmid + IL-2 complexes; right panel, summary plot over time. For CD4+CD25+Foxp3+ T cells gated on CD4+ T cells, (b) left panel, representative dot plot from mice treated with FVIII plasmid + IL-2 complexes; right panel, summary plot over time, and (c) the expression levels of their activation markers (shown by median fluorescence intensity (MFI) values): CD25, CD62L, glucocorticoid-induced tumor necrosis factor receptor (GITR) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) at days 1, 3, 7, and 28 after FVIII plasmid transfer. Data shown are MFI value of the four activation markers of each group.